Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Passage Bio ( (PASG) ).
On June 23, 2025, Passage Bio announced updated interim data from their Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for frontotemporal dementia with GRN mutations. The data showed a significant increase in cerebrospinal fluid progranulin levels and a reduced rate of plasma neurofilament increase, indicating a potential therapeutic benefit. The company plans to amend the trial protocol to include prophylactic anticoagulation and adjust inclusion criteria, with further regulatory feedback and trial design discussions anticipated in 2026.
The most recent analyst rating on (PASG) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.
Spark’s Take on PASG Stock
According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.
Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company’s stage and lack of profitability.
To see Spark’s full report on PASG stock, click here.
More about Passage Bio
Passage Bio is a clinical stage genetic medicines company focused on developing therapies for neurodegenerative diseases. Their primary product candidate, PBFT02, aims to treat conditions such as frontotemporal dementia by elevating progranulin levels to improve lysosomal function and slow disease progression.
Average Trading Volume: 244,387
Technical Sentiment Signal: Sell
Current Market Cap: $24.3M
For an in-depth examination of PASG stock, go to TipRanks’ Overview page.